QSA congratulates Autolus for achieving its historic milestone dosing the first patient with its pioneering BOBCAT trial of obecabtagene autoleucel (obe-cel), a ‘one-time’ immunotherapy treatment for progressive multiple sclerosis (PMS). QSA is providing advanced imaging analytics in support of this groundbreaking work.
Publication
Autolus Pioneers CAR-T Cell MS Treatment
Planning a neurology trial?
Tell us about your study and the imaging questions behind it.